Baird Downgrades Regeneron Pharma (REGN) to Neutral; EPS Expectations Will Be Hard to Meet
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
Baird downgraded Regeneron Pharma (NASDAQ: REGN) from Outperform to Neutral with a price target of $488.00 (from $505.00) following Q2 results.
Analyst Brian Skorney commented, "Regeneron posted an EPS beat in the second quarter, driven by operating expense adjustments. Though Eylea sales growth remains strong, after a thorough model review, we think the consensus EPS expectations over the 2017/18 time frame will be hard to meet without a 15-20% downward revision. Near term, with high expectations for dupilumab and sarilumab sales baked in, a slow Praluent launch, and opex set to increase, we are comfortable moving to the sidelines and lowering our price target to $448."
The firm cut FY 2016 EPS from $11.69 to $11.02 and FY 2017 EPS from $15.13 to $12.83.
Shares of Regeneron Pharma closed at $433.40 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- UPDATE: BMO Capital Upgrades Williams Partners LP (WPZ) to Outperform
- Guggenheim Starts Achaogen (AKAO) at Buy; Positive on Plazomicin Approval, Seen as Takeout Target
- Clovis Oncology (CLVS) PT Raised to $86 as Stifel Adopts Takeout Valuation
Create E-mail Alert Related CategoriesAnalyst Comments, Analyst EPS Change, Analyst EPS View, Analyst PT Change, Downgrades, Hot Downgrades
Related EntitiesRobert W Baird
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!